Kura Oncology to Contribute to the Healthcare Dialogue
Kura Oncology, Inc. (NASDAQ: KURA), based in San Diego, is a pioneering clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through precision medicine. This commitment will be highlighted at the upcoming investor conference where they will present their innovative approaches and future aspirations in oncological therapies.
Details of the Investor Conference
Kura Oncology will be participating in the Jefferies Global Healthcare Conference. The event is set to take place on November 19, 2025, at 3:30 p.m. GMT, corresponding to 10:30 a.m. ET and 7:30 a.m. PT. Attendees can look forward to insights into the company's forward-thinking strategies and their ongoing mission in cancer care.
Accessing the Webcast
For those unable to attend in person, Kura will provide a live audio webcast. Investors and interested parties can access this through the Kura Oncology website. Moreover, an archived version of the presentation will be available for later viewing, ensuring that all interested individuals can remain updated on Kura's developments and initiatives in the industry.
About Kura Oncology's Focus
Kura Oncology is steadfast in its mission to innovate treatments targeting high-need hematologic malignancies and solid tumors. The company's portfolio features a range of small molecule drug candidates specifically designed to target critical cancer signaling pathways.
Innovative Treatments on the Horizon
One of the flagship projects being developed is ziftomenib, which functions as a menin inhibitor. This targeted therapy is intended for patients with certain genetic mutations linked to acute myeloid leukemia (AML). By focusing on high-need cancer treatments, Kura Oncology aims to address not only the disease itself but also the resistance mechanisms that often hinder successful therapy.
Pipeline of Innovation
In addition to ziftomenib, Kura is actively involved in advancing its pipeline with therapies that employ farnesyl transferase inhibition. This approach looks to combat adaptive resistance mechanisms in solid tumors, showcasing Kura's innovative strategy to enhance treatment efficacy.
Community Engagement and Transparency
Kura Oncology is committed to transparency and community engagement. The details of their research and upcoming advancements are shared openly as part of their mission to keep stakeholders informed and involved in their journey toward making a significant impact in cancer care.
Contacting Kura Oncology
For inquiries related to investments or media coverage, Greg Mann is the primary contact. He can be reached at 858-987-4046. Kura encourages dialogue with investors and the media alike to foster broader understanding of their operations and research.
Frequently Asked Questions
What is Kura Oncology's primary focus?
Kura Oncology focuses on developing precision medicines targeting cancer, specifically hematologic malignancies and solid tumors.
When is the Jefferies Global Healthcare Conference?
The conference will take place on November 19, 2025, at 3:30 p.m. GMT.
How can I access the live webcast?
The live webcast can be accessed through the Investors section on Kura Oncology's official website.
What notable projects is Kura working on?
Kura is developing ziftomenib, a menin inhibitor for acute myeloid leukemia, and exploring farnesyl transferase inhibition therapies.
How can I contact Kura Oncology?
Contact Greg Mann at 858-987-4046 for any investment or media inquiries regarding Kura Oncology.